top of page

EC approves Daklinza in three new HCV patient populations

The European Commission has approved Bristol-Myers Squibb’s Daklinza (daclatasvir) for the treatment of chronic hepatitis C (HCV) in three new patient populations.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page